^
Association details:
| Biomarker: | FLT3 Y842H |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Vanflyta (quizartinib) (FLT3 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Excerpt:
The five substitutions that conferred a high degree of resistance to AC220 in vitro were cross-resistant to sorafenib in cell-based growth and biochemical assays (Supplementary Fig. 4). The degree of relative resistance to sorafenib associated with these mutants was generally similar to that observed with AC220.
DOI:
https://dx.doi.org/10.1038%2Fnature11016
Trial ID:
